Pharmascience Inc. Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Pharmascience Inc. Pharmaceutical Import Records from India — 6 Products, $4.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Pharmascience Inc. — Pharmaceutical Importer Profile (2026) | 6 Products, $4.3M Trade | TransData Nexus

Pharmascience Inc.

Pharmaceutical Importer · Canada · Cardiovascular Focus · $4.3M Total Trade · DGFT Verified

Pharmascience Inc. is a pharmaceutical importer based in Canada with a total trade value of $4.3M across 6 products in 6 therapeutic categories. Based on 97 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Pharmascience Inc. sources from 1 verified Indian supplier, with Cipla Limited accounting for 100.0% of imports.

Pharmascience Inc. — Import Portfolio & Supplier Network

Pharmascience Inc. import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Pharmascience Inc.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$835.8K	31	100.0%

Pharmascience Inc. sources from 1 verified Indian supplier across 21 distinct formulations. The sourcing is highly concentrated — Cipla Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Pharmascience Inc. Import?

Formulation	Value	Ships
Pms - nifedipine er 60 MG tablet ( inv.	$200.0K	4
Pms - letrozole 2.5 MG tablets (letrozole 2.5MG) (inv.qty.9200 Pack 3x10's= 276000 nos)	$150.0K	3
Pms - nifedipine er 60 MG tablet (inv.qty.4368 Pack 1x100s=436800 nos)	$129.6K	3
Pms - letrozole 2.5 MG tablets (letrozole 2.5MG) (inv.qty.8990 Pack 3x10's=269700 nos)	$56.2K	3
Nifedipine er 60 MG tablet ( inv.	$50.0K	1
Pms - nifedipine er 60 MG tablet (inv.qty.4560 Pack 1x100s=456000 nos)	$50.0K	1
Nifedipine er 60 MG tablet (inv.qty.4416 Pack 1x100s=441600 nos)	$50.0K	1
Nifedipine er 60 MG tablet . ( inv/qty.4554 Pack 1 x 100's = 455400 nos)	$50.0K	1
Pms - nifedipine er 60 MG tablet ( inv.qty. 4560 Pack 1 x 100's =456000 nos )	$50.0K	1
Pms - letrozole 2.5 MG tablets (letrozole 2.5MG) (inv.qty.9090 Pack 3x10's= 272700 nos)	$50.0K	1
We intend to claim benefit under	$0	1
Shipment on payment of igst ,under	$0	1
I/we undertake to abide by the	$0	1
We intend to claim benefit under rodtepscheme . (6 pallets containing 187 shippers)	$0	1
Shipment on payment of igst ,under refund (tax inv no.1301421800 dt.25.12.2023)	$0	1

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Nifedipine	Cardiovascular	$1.6M	35	3.7%	5
2	Dapagliflozin	Advanced Diabetes Medications	$1.3M	32	1.5%	16
3	Naproxen	Analgesics & Antipyretics	$600.0K	12	0.4%	16
4	Hydrochlorothiazide	Diuretics	$450.0K	9	0.1%	2
5	Letrozole	Advanced Oncology	$271.7K	7	0.8%	12
6	Terbinafine	Antifungals	$100.0K	2	0.4%	17

Pharmascience Inc. imports 6 pharmaceutical products across 6 categories into Canada totaling $4.3M.

Pharmascience Inc. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Pharmascience Inc. is a privately held pharmaceutical company headquartered in Montreal, Quebec, Canada. Established in 1983 by pharmacists Morris Goodman and Ted Wise, the company has grown to become the largest Canadian-owned pharmaceutical manufacturer and the largest pharmaceutical employer in Quebec, employing over 1,600 individuals. Pharmascience specializes in the development, manufacturing, and distribution of generic, branded, and over-the-counter pharmaceuticals, serving both the Canadian and international markets. With a portfolio of over 1,300 stock-keeping units (SKUs) across 300 molecules, the company distributes its products to more than 50 countries worldwide.

In 2024, Pharmascience was recognized by Great Place to Work as one of the Top 50 Best Workplaces in Canada, reflecting its commitment to employee satisfaction and organizational excellence. The company's mission is to make essential treatments affordable, ensuring the well-being of the communities it serves.

2Distribution Network

Pharmascience operates a robust distribution network to support its global operations. The company's primary manufacturing and distribution facilities are located in Montreal and Candiac, Quebec. These state-of-the-art facilities enable Pharmascience to produce and distribute a wide range of pharmaceutical products efficiently. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, Pharmascience's extensive distribution network ensures that its products are available in over 50 countries, meeting the needs of both domestic and international markets.

3Industry Role

Pharmascience Inc. plays a pivotal role in Canada's pharmaceutical supply chain as a leading manufacturer and distributor of generic and branded medications. The company serves as a primary wholesaler, supplying pharmaceutical products to hospitals, pharmacies, and other healthcare providers across Canada. Its extensive product portfolio and manufacturing capabilities position Pharmascience as a key player in ensuring the availability of affordable and high-quality medicines within the Canadian healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Pharmascience Inc.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Pharmascience's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a single supplier, CIPLA LIMITED. The company's total import value from India stands at $4.3 million USD, with 97 shipments comprising 21 unique formulations. CIPLA LIMITED accounts for $836,000 USD of this total, representing 31 shipments and 100% of the Indian suppliers.

This sourcing concentration indicates a strategic partnership between Pharmascience and CIPLA LIMITED, potentially leading to favorable terms and streamlined supply chain operations. However, such dependency also introduces risks related to supply chain disruptions, regulatory changes, or geopolitical factors affecting the supplier's operations. The stability of this relationship is crucial for Pharmascience's ability to maintain a consistent supply of pharmaceutical products.

2Supply Chain Resilience

Pharmascience's supply chain resilience is closely tied to its reliance on CIPLA LIMITED as the primary supplier for its pharmaceutical imports from India. The company's import data reveals a high degree of concentration, with CIPLA LIMITED accounting for 100% of the Indian suppliers.

This single-source dependency may pose challenges in terms of supply chain flexibility and responsiveness to market changes. The absence of backup suppliers for Indian imports suggests a need for strategic diversification to mitigate potential risks. Additionally, the limited diversity in imported formulations, with only 21 unique formulations, may impact Pharmascience's ability to adapt to evolving market demands.

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the regulation of pharmaceutical imports is overseen by Health Canada, the federal department responsible for national public health. The importation and exportation of health products, including pharmaceuticals, are governed by the Food and Drugs Act and its associated Regulations. (canada.ca)

Health Canada's regulatory framework ensures that all imported pharmaceutical products meet stringent safety, efficacy, and quality standards before they are authorized for sale in Canada. This includes a comprehensive evaluation process for new drug submissions, as well as ongoing monitoring and compliance activities to maintain the integrity of the Canadian pharmaceutical market.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Canada are stringent, with all imported drugs required to be authorized by Health Canada before they can be sold or distributed. This process involves a thorough review of the product's safety, efficacy, and quality data. (canada.ca)

Good Manufacturing Practice (GMP) certification is a critical component of the import authorization process. Health Canada recognizes GMP certifications from reputable international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Pharmaceutical manufacturers seeking to export to Canada must ensure that their facilities comply with these recognized GMP standards to facilitate the importation process.

Pharmascience Inc. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Pharmascience's product strategy focuses on therapeutic areas such as cardiovascular, advanced diabetes medications, and analgesics & antipyretics. The company's import data indicates that these categories constitute a significant portion of its pharmaceutical imports from India.

The emphasis on these therapeutic areas aligns with the growing demand for treatments addressing chronic conditions prevalent in Canada. By focusing on these segments, Pharmascience aims to provide essential medications that improve patient outcomes and quality of life.

2Sourcing Profile

Pharmascience's sourcing strategy for generic drugs involves importing finished pharmaceutical formulations from India, with a notable concentration on products from CIPLA LIMITED. This approach allows Pharmascience to leverage India's manufacturing capabilities and cost advantages while ensuring product quality.

The company's preference for finished formulations over raw active pharmaceutical ingredients (APIs) indicates a focus on ready-to-market products, streamlining the supply chain and reducing time to market. India's established pharmaceutical industry, with its adherence to international quality standards, makes it a strategic partner for Pharmascience's procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Pharmascience Inc.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

Pharmascience's sourcing pattern, characterized by a high degree of concentration with CIPLA LIMITED, presents both challenges and opportunities for new Indian suppliers. While the existing partnership may limit immediate opportunities, Pharmascience's emphasis on affordability and quality suggests potential interest in exploring alternative suppliers that can meet these criteria.

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Pharmascience Inc.

What products does Pharmascience Inc. import from India?

Pharmascience Inc. imports 6 pharmaceutical products across 6 categories. Top imports: Nifedipine ($1.6M), Dapagliflozin ($1.3M), Naproxen ($600.0K), Hydrochlorothiazide ($450.0K), Letrozole ($271.7K).

Who supplies pharmaceuticals to Pharmascience Inc. from India?

Pharmascience Inc. sources from 1 verified Indian suppliers. The primary supplier is Cipla Limited (100.0% of imports, $835.8K).

What is Pharmascience Inc.'s total pharmaceutical import value?

Pharmascience Inc.'s total pharmaceutical import value from India is $4.3M, based on 97 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Pharmascience Inc. focus on?

Pharmascience Inc. imports across 6 categories. The largest: Cardiovascular (36.9%), Advanced Diabetes Medications (30.3%), Analgesics & Antipyretics (13.8%).

Get Full Pharmascience Inc. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.